Sakar Healthcare Ltd Stock Price Today (NSE: SAKAR)
Fundamental Score
Sakar Healthcare Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Sakar Healthcare Ltd share price today is ₹498.45, down 2.69% on NSE/BSE as of 30 March 2026. Sakar Healthcare Ltd (SAKAR) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹863.07 (Cr). The 52-week high for SAKAR share price is ₹577.95 and the 52-week low is ₹214.30. At a P/E ratio of 44.17x, SAKAR is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 6.48% and a debt-to-equity ratio of 0.24.
Sakar Healthcare Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Sakar Healthcare Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Sakar Healthcare Share Price Analysis: A Growth Strategist's Perspective
The Sakar Healthcare share price currently stands at ₹437.299988. In the dynamic pharmaceutical landscape, where innovation and regulatory navigation are paramount, assessing a company's financial health is crucial. This analysis delves into Sakar Healthcare Ltd's key financial metrics, specifically focusing on its Price-to-Earnings (PE) ratio and Return on Capital Employed (ROCE), to understand its competitive positioning and growth potential. A key factor for industry dominance lies in robust R&D pipelines coupled with efficient manufacturing.
Sakar Healthcare's PE ratio of 44.17 suggests a valuation that is substantially higher than some benchmarks. This premium implies investor expectations of strong future earnings growth. However, to properly assess this, a comparison with sector peers is essential. While a direct comparison is outside the scope here, one should consider aspects like management quality. For instance,
Mankind Pharma Ltd has demonstrated strong execution capabilities which is reflected in its own market valuation. Management's track record in navigating regulatory hurdles and driving product launches profoundly impacts investor confidence and therefore, share price.A critical factor to evaluate is Sakar Healthcare Ltd's ROCE of 8.54%. ROCE is a measure of how effectively a company is using its capital to generate profits. An ROCE of 8.54% suggests that, for every ₹100 invested, the company generates ₹8.54 in earnings. This figure is quite telling when we think about the creation of an economic moat. A lower ROCE in comparison to competitors may indicate constraints in generating returns on investments, potentially limiting the company's ability to re-invest and develop new products, thus hindering the widening of its moat within the generics market. The sustainability of competitive advantages is directly linked to ROCE.
Further detailed financial analysis would be required to build a comprehensive strategy. This initial observation is part of a broader, 80-parameter fundamental audit of Sakar Healthcare Ltd. This audit was verified by Sweta Mishra, and provides a deeper, holistic view of the company's strengths and areas needing improvement. This analysis is purely observational and does not constitute investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Sakar Healthcare Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SAKAR across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Operating Margins (25.29%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Revenue Growth (34.55%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (16.43% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Conservative Debt Levels (D/E: 0.24)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (52.86%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (6.48%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (8.54%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 44.17x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (4.60% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Negative Free Cash Flow (₹-176.20 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Sakar Healthcare Ltd Financial Statements
Comprehensive financial data for Sakar Healthcare Ltd including income statement, balance sheet and cash flow
About SAKAR (Sakar Healthcare Ltd)
Sakar Healthcare Ltd is a dynamic pharmaceutical company committed to innovation and quality in healthcare solutions. Focused on both domestic and international markets, Sakar Heal...thcare meticulously crafts and distributes a diverse range of pharmaceutical formulations. Their expertise lies in the production of various dosage forms, including complex sterile injectables, meticulously crafted oral solids, and palatable liquid formulations. Through advanced manufacturing processes and stringent quality control measures, Sakar Healthcare ensures that each product adheres to the highest industry standards. The company consistently strives to meet the evolving healthcare needs of patients worldwide by delivering safe, effective, and affordable medicines. Sakar Healthcare demonstrates a dedication to developing cutting-edge pharmaceutical products and processes. With a team of skilled scientists and researchers, the company invests significant resources in research and development to create innovative solutions. This commitment extends to improving existing formulations and exploring new therapeutic avenues. Sakar Healthcare emphasizes compliance with regulatory guidelines and global best practices in pharmaceutical manufacturing. This commitment underscores their ambition to be a trusted partner in healthcare, providing reliable and high-quality products to enhance patient outcomes and overall well-being. Sakar Healthcare's comprehensive product portfolio spans a wide spectrum of therapeutic areas, addressing critical healthcare needs across diverse patient populations. From addressing common infections with anti-infectives to managing pain with analgesics, the company offers a range of essential medications. Furthermore, they cater to specialized treatment areas, including antihistamines for allergies, anthelmintics for parasitic infections, and anti-malarials for malaria. Sakar Healthcare aims to provide affordable access to essential medicines to improve lives and promote better health outcomes across the globe. They continuously adapt their product offerings to meet the changing needs of the healthcare landscape.
Company Details
Key Leadership
SAKAR Share Price: Frequently Asked Questions
What is the current share price of Sakar Healthcare Ltd (SAKAR)?
As of 30 Mar 2026, 12:04 pm IST, Sakar Healthcare Ltd share price is ₹498.45. The SAKAR stock has a market capitalisation of ₹863.07 (Cr) on NSE/BSE.
Is SAKAR share price Overvalued or Undervalued?
SAKAR share price is currently trading at a P/E ratio of 44.17x, compared to the industry average of 31.77x. Based on this relative valuation, the Sakar Healthcare Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of SAKAR share price?
The 52-week high of SAKAR share price is ₹577.95 and the 52-week low is ₹214.30. These values are updated daily from NSE/BSE price data.
What factors affect the Sakar Healthcare Ltd share price?
Key factors influencing SAKAR share price include quarterly earnings growth (Sales Growth: 34.55%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Sakar Healthcare Ltd a good stock for long-term investment?
Sakar Healthcare Ltd shows a 5-year Profit Growth of 12.94% and an ROE of 6.48%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.24 before investing in SAKAR shares.
How does Sakar Healthcare Ltd compare with its industry peers?
Sakar Healthcare Ltd competes with major peers in the Pharmaceuticals. Investors should compare SAKAR share price P/E of 44.17x and ROE of 6.48% against the industry averages to determine competitive standing.
What is the P/E ratio of SAKAR and what does it mean?
SAKAR share price has a P/E ratio of 44.17x compared to the industry average of 31.77x. Investors pay ₹44 for every ₹1 of annual earnings.
How is SAKAR performing according to Bull Run's analysis?
SAKAR has a Bull Run fundamental score of 43.9/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does SAKAR belong to?
SAKAR operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Sakar Healthcare Ltd share price.
What is Return on Equity (ROE) and why is it important for SAKAR?
SAKAR has an ROE of 6.48%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Sakar Healthcare Ltd generates profits from shareholders capital.
How is SAKAR debt-to-equity ratio and what does it indicate?
SAKAR has a debt-to-equity ratio of 0.24, which indicates conservative financing with low financial risk.
What is SAKAR dividend yield and is it a good dividend stock?
SAKAR offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Sakar Healthcare Ltd shares.
How has SAKAR share price grown over the past 5 years?
SAKAR has achieved 5-year growth rates of: Sales Growth 16.43%, Profit Growth 12.94%, and EPS Growth 4.60%.
What is the promoter holding in SAKAR and why does it matter?
Promoters hold 52.86% of SAKAR shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Sakar Healthcare Ltd.
What is SAKAR market capitalisation category?
SAKAR has a market capitalisation of ₹863 crores, placing it in the Small-cap category.
How volatile is SAKAR stock?
SAKAR has a beta of N/A. A beta > 1 suggests the Sakar Healthcare Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is SAKAR operating profit margin trend?
SAKAR has a 5-year average Operating Profit Margin (OPM) of 25.29%, indicating the company's operational efficiency.
How is SAKAR quarterly performance?
Recent quarterly performance shows Sakar Healthcare Ltd YoY Sales Growth of 34.55% and YoY Profit Growth of -5.42%.
What is the institutional holding pattern in SAKAR?
SAKAR has FII holding of 13.31% and DII holding of 11.43%. Significant institutional holding often suggests professional confidence in the Sakar Healthcare Ltd stock.